1
Izumimoto Naoki, Kawamura Kuniaki, Komagata Toshikazu, Hashimoto Tadatoshi, Nagabukuro Hiroshi: (Ja) 鎮痛剤, (En) Analgesic. Toray Industries, Izumimoto Naoki, Kawamura Kuniaki, Komagata Toshikazu, Hashimoto Tadatoshi, Nagabukuro Hiroshi, TANIGAWA Hidejiro, May 11, 2006: WO/2006/049248 (8 worldwide citation)

(EN) An analgesic widely applicable to various pains induced by various causes. The analgesic contains as an active ingredient either a specific morphinan derivative having a nitrogenous cyclic substituent in the 6-position such as compound (1), or a pharmacologically acceptable acid addition salt t ...


2
Kamo Izumi, Hashimoto Tadatoshi: (Ja) 腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法. Takeda Pharmaceutical Company, Kamo Izumi, Hashimoto Tadatoshi, TAKASHIMA Hajime, March 2, 2006: WO/2006/022420 (3 worldwide citation)

(EN) It is intended to provide a preventive/remedy for stress urinary incontinence which contains a substance activating serotonin 5-HT2C receptor; a preventive/remedy for stress urinary incontinence which contains a substance stimulating an androgen-binding site; and a method of screening a prevent ...


3
Ikeura Yoshinori, Hashimoto Tadatoshi, Nishida Haruyuki, Shirai Junya, Sakauchi Nobuki: (Ja) ピペリジン誘導体およびその用途, (En) Piperidine derivatives and use thereof. Takeda Pharmaceutical Company, Ikeura Yoshinori, Hashimoto Tadatoshi, Nishida Haruyuki, Shirai Junya, Sakauchi Nobuki, TAKASHIMA Hajime, March 23, 2006: WO/2006/030975 (2 worldwide citation)

(EN) Compounds represented by the general formula (&Igr;) or salts thereof; and preventive and therapeutic drugs for lower urinary tract dysfunction and so on, containing the compounds or the salts: wherein Ar is optionally substituted aryl; R is C1-6 alkyl; R1 is hydrogen, an optionally substituted ...


4
Ikeura Yoshinori, Hashimoto Tadatoshi, Tarui Naoki, Kamo Izumi, Shirai Junya: Tricyclic heterocyclic compound, process for producing the same, and use thereof. Takeda Chemical Industries, Ikeura Yoshinori, Hashimoto Tadatoshi, Tarui Naoki, Kamo Izumi, Shirai Junya, TAKASHIMA Hajime, March 21, 2002: WO/2002/022574 (1 worldwide citation)

A compound represented by the formula, a salt thereof, or a prodrug thereof: (I) wherein R?1¿ represents hydrogen, optionally substituted alkyl, aryl, acyl, alkoxycarbonyl, carbamoyl, mono- or dialkylcarbamoyl, or alkylsulfonyl; R?2¿ represents hydrogen, halogeno, or optionally halogenated alkyl; R? ...


5
Ito Yasuaki, Fujii Ryo, Kobayashi Makoto, Hinuma Shuji, Hashimoto Tadatoshi, Tanaka Yasuhiro: (Ja) 新規スクリーニング方法, (En) Novel screening method. Takeda Pharmaceutical Company, Ito Yasuaki, Fujii Ryo, Kobayashi Makoto, Hinuma Shuji, Hashimoto Tadatoshi, Tanaka Yasuhiro, TAKAHASHI Shuichi, November 11, 2004: WO/2004/097411 (1 worldwide citation)

(EN) By using a G protein-coupled receptor protein having an amino acid sequence which is the same or substantially the same as the amino aid sequence represented by SEQ ID NO:1 or its salt and an ion chemically available metal element or its salt, an agonist or an antagonist to the above receptor p ...


6
Ohkawa Shigenori, Hashimoto Tadatoshi, Tsukamoto Tetsuya: Tricyclic dihydrobenzofuran derivatives, process for the preparation thereof and agents. Takeda Chemical Industries, Ohkawa Shigenori, Hashimoto Tadatoshi, Tsukamoto Tetsuya, TAKAHASHI Shuichi, March 1, 2001: WO/2001/014384

Compounds represented by general formula (1) or salts thereof exhibit excellent inhibitory activity against the formation of peroxylipid and are useful as inhibitors against the formation thereof. In said formula, A is a nonaromatic five- to seven-membered nitrogenous heterocycle which may be additi ...


7
Ohkawa Shigenori, Hashimoto Tadatoshi, Tsukamoto Tetsuya: Dihydrobenzofuran derivatives, process for the preparation thereof and agents. Takeda Chemical Industries, Ohkawa Shigenori, Hashimoto Tadatoshi, Tsukamoto Tetsuya, TAKAHASHI Shuichi, March 1, 2001: WO/2001/014385

Compounds represented by general formula (I) or salts thereof exhibit excellent inhibitory activity against the formation of peroxylipid and are useful as inhibitors against the formation thereof wherein A is a nonaromatic five- to seven-membered nitrogenous heterocycle which may be additionally sub ...


8
Ohkawa Shigenori, Hashimoto Tadatoshi, Fukatsu Kohji: Cyclic ether compounds as sodium channel modulators. Takeda Chemical Industries, Ohkawa Shigenori, Hashimoto Tadatoshi, Fukatsu Kohji, sASAHINA Tadao, March 5, 1998: WO/1998/008842

A compound of formula (I) wherein R?1¿ and R?2¿ each represents hydrogen, lower alkyl which may be substituted or acyl; R?3¿, R?4¿ and R?5¿ each represents lower alkyl which may be substituted or lower alkoxy which may be substituted or R?4¿ and R?5¿ taken together represent a 5- or 6-membered carbo ...


9
Ikeura Yoshinori, Hashimoto Tadatoshi, Tarui Naoki, Shirai Junya, Yamashita Masayuki: Piperidine derivative, process for producing the same, and use. Takeda Pharmaceutical Company, Ikeura Yoshinori, Hashimoto Tadatoshi, Tarui Naoki, Shirai Junya, Yamashita Masayuki, TAKAHASHI Shuichi, December 11, 2003: WO/2003/101964

A novel piperidine derivative (I) which is either a compound represented by the formula (I) (wherein Ar represents an aryl, aralkyl, or aromatic heterocyclic group which may have one or more substituents; R1 represents hydrogen, an optionally substituted hydrocarbon group, acyl, or an optionally sub ...


10
Yamaoka Masayoshi, Ikeura Yoshinori, Hashimoto Tadatoshi, Tarui Naoki: Nitrogenous cyclic ketone derivative, process for producing the same, and use. Takeda Chemical Industries, Yamaoka Masayoshi, Ikeura Yoshinori, Hashimoto Tadatoshi, Tarui Naoki, AOYAMA Tamotsu, July 17, 2003: WO/2003/057668

A novel compound represented by the formula (I): (I) wherein rings A and B each represents an optionally substituted aromatic ring, or rings A and B may be bonded to each other through linking between bonds or substituents thereof to form a ring; ring C represents a nitrogenous saturated ...